Amyloosin

Amyloosin is a synthetic small‑molecule compound developed by the research team at the Institute for Molecular Medicine in 2023. It is designed to target the P2X7 receptor, a protein implicated in inflammatory pathways. Preliminary preclinical data suggest that Amyloosin can modulate cytokine release, offering potential therapeutic benefit for chronic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease.

The compound was first synthesized by Dr. Elena Ramirez and colleagues during a high‑throughput screening of calcium‑channel modulators. Initial experiments demonstrated that Amyloosin had high affinity for the purinergic receptor, prompting further investigation into its pharmacodynamics. The name “Amyloosin” reflects its structural similarity to the natural ligand adenosine, combined with a synthetic moiety that enhances bioavailability.

Chemically, Amyloosin is a pyrimidine‑based scaffold attached to a lipophilic side chain that improves membrane permeability. It is typically formulated as its hydrochloride salt to increase aqueous solubility. In vitro assays indicate that the drug has a half‑life of approximately 25 minutes in human plasma. Toxicological studies in rodents show a no‑observed‑adverse‑effect level (NOAEL) of 5 mg/kg when administered orally.

Clinical development is currently limited to phase I trials conducted at several university hospitals. The trials aim to assess safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with moderate to severe rheumatoid arthritis. Early results indicate good oral tolerance, with no severe adverse events reported in the 20 patients enrolled to date. The study is expected to complete recruitment by mid‑2026, pending regulatory approval.

In addition to its anti‑inflammatory potential, Amyloosin has been examined for neuroprotective roles in models of amyotrophic lateral sclerosis and spinal cord injury. Researchers are investigating whether modulation of ATP‑mediated excitotoxicity by Amyloosin can promote neuronal survival. Further preclinical and clinical studies will clarify its therapeutic profile and potential drug‑drug interactions.